All In Biotech

Drug Trial Radar · NCT00041483

Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMD

Last checked: Nov 20, 2026Latest source record: Jul 1, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 530 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

530

Actual

Start

Jun 2002

Primary completion

Aug 2005

Study completion Aug 2005

Sponsor

Lead sponsor
Alcon ResearchIndustry
Sponsor type
Industry
First posted
Aug 1, 2002

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to demonstrate that Anecortave Acetate is as effective after twelve months of treatment as photodynamic therapy (PDT) with Visudyne in patients eligible for initial PDT treatment for wet age-related macular degeneration.

Conditions

  • Macular Degeneration

Interventions

  • Anecortave Acetate 15 mg sterile suspensionDrug

  • Photodynamic Therapy (PDT)Other

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Patients Maintaining VisionTime frame: Month 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Contact Alcon Call Center for Trial Locations

    Fort Worth, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.